<?xml version="1.0" encoding="UTF-8"?>
<p id="Par28">When further stratifying patients according to NAs drugs, clinical manifestations of lipodystrophy were observed in 7/20 (35%) patients receiving lamivudine + adefovir, in 3/19 (15.7%) among patients treated with tenofovir and in 0/11(0%) of patients receiving entecavir. It is noteworthy that 2/3 patients with BSC currently receiving tenofovir had previously been exposed to lamivudine + adefovir.</p>
